Futura Medical PLC Notice of Interim Results (6102I)
12 Agosto 2019 - 1:00AM
UK Regulatory
TIDMFUM
RNS Number : 6102I
Futura Medical PLC
12 August 2019
Notice of Interim Results
12 August 2019
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal Dermasys(R) drug delivery technology and
currently focused on sexual health and pain, will announce its
interim results for the six months ended 30 June 2019 and provide a
trading update on Wednesday 11 September 2019.
James Barder, Chief Executive Officer, Angela Hildreth, Finance
Director/Chief Operating Officer and Ken James, Executive Director
and Head of R&D, will host a presentation for analysts at 10am
BST on the day of the results at the office of Liberum Capital at
25 Ropemaker Street, London, EC2Y 9LY.
Analysts wishing to attend the presentation should register
their interest by emailing futuramedical@optimumcomms.com.
A copy of the announcement will be made available on the Futura
Medical website and following the results meeting a webcast of the
presentation to analysts will also be made available within the
Investor Centre section of the site.
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal Dermasys(R) drug delivery technology.
These products are optimised for clinical efficacy, safety,
administration and patient convenience and are developed for the
prescription and consumer healthcare markets as appropriate.
Current therapeutic areas are sexual health, including erectile
dysfunction, and pain relief. Development and commercialisation
strategies are designed to maximise product differentiation and
value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as
"FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised,
double blind, placebo-controlled, home use, parallel group study of
MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment
of erectile dysfunction with an open label extension. FM57 is
progressing on track, with headline data expected by the end of
2019.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORSSLFDUFUSEIA
(END) Dow Jones Newswires
August 12, 2019 02:00 ET (06:00 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024